<?xml version="1.0" encoding="UTF-8"?>

<?xml-stylesheet type="text/xsl" href="/static/oaitohtml.xsl"?>

<!--
<?xml-stylesheet type="text/xsl" href="/oaitohtml.xsl"?>
-->

<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <responseDate>2026-10-12T16:55:11Z</responseDate>
    <request verb="GetRecord" metadataPrefix="oai_dc" identifier="10.57760/sciencedb.26342" >https://www.scidb.cn/oai</request>
<GetRecord>
    <record>
    <header >
    <identifier>10.57760/sciencedb.26342</identifier>
    <datestamp>2025-06-18T16:37:42Z</datestamp>
</header>
    <metadata>
        
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:date>2025-06-18</dc:date>
  <dc:title>Multi-Epitope Vaccine Against African Swine Fever Virus Designed Through Reverse Vaccinology and Genomic Analysis with Experimental Validation of Immunogenicity</dc:title>
  <dc:identifier>doi:10.57760/sciencedb.26342</dc:identifier>
  <dc:language>en</dc:language>
  <dc:description>African swine fever (ASF), a highly pathogenic and lethal disease caused by the African swine fever virus (ASFV), poses a critical threat to global swine production, with no licensed vaccines currently available. This study employed whole-genome analysis of representative ASFV strains (genotypes I, II and recombinant variants) combined with reverse vaccinology to screen linear B-lymphocyte (LBL), cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL) epitopes for multi-epitope vaccine development. The designed vaccine comprised 36 antigenic epitopes derived from 18 consensus proteins across six representative ASFV strains, demonstrating high immunogenicity, non-toxicity, non-allergenicity and favorable physicochemical stability. Molecular docking revealed strong binding affinity between the vaccine candidate and Toll-like receptor 4 (TLR4). Immunization experiments in mice demonstrated significant induction of specific antibodies alongside robust humoral and cellular immune responses. These findings underscore the vaccine&amp;rsquo;s potential for comprehensive prevention against diverse ASFV strains, providing a pivotal foundation for advancing ASF vaccine development.</dc:description>
  <dc:subject>ASFV; multi-epitope vaccine; reverse vaccinology; immunoinformatics; immunogenicity</dc:subject>
  <dc:creator>ZHU Bo</dc:creator>
  <dc:rights>PUBLIC</dc:rights>
  <dc:rights>https://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
  <dc:type>dataset</dc:type>
  <dc:publisher>Science Data Bank</dc:publisher>
</oai_dc:dc>

    </metadata>
</record>
</GetRecord>
</OAI-PMH>